Group Publications (last three years)
Garcia Martin, Margarita; Perez Martin, Xavier; Camina Moncayo, Cristina; Germa Luch, Josep Ramon. 2010. [Patterns of participation in clinical trials among cancer patients: a prospective study]. Med Clin (Barc) 134 (13):591-5.
García M, Clopés A, Bruna J, Martínez M, Fort E, Gil M. Critical appraisal of temozolomide formulations in the treatment of primary brain tumors: patient considerations. Cancer Manag Res. 2009 Oct 30;1:137-50.
Collaborations
Pardo B, Salazar R, Ciruelos E, Cortés-Funes H, García M, Majem M, Montes A, Cuadra C, Soto-Matos A, Lebedinsky C, Alfaro V, Paz-Ares L. “Phase I and pharmacokinetic study of trabectedin 3-hour infusion every three weeks in patients with advanced cancer and alteration of hepatic function”. Med Oncol. 2011 Jun 10.
Vidal L, Magem M, Barlow C, Pardo B, Florez A, Montes A, Garcia M, Judson I, Lebedinsky C, Kaye SB, Salazar R. “Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors”. Invest New Drugs. 2010.
Majem M, Salazar R, Garcia M, Clopes A, Muñoz C, Pardo B, Martinez M, Cuadra C, Montes A, Mis R, Savulsky C, Ramon Germa-Lluch J. “A phase I clinical and pharmacokinetic study (LIPOTEC - GP PHARM/DOXO 01) of a new liposomal doxorubicin given as 3-week schedule in patients with solid tumors”. J Liposome Res. 2009.
Schoffski, P; Guillem, V; Garcia, M; Rivera, F; Tabernero, J; Cullell, M; Lopez-Martin, JA; Pollard, P; Dumez, H; del Muro, XG; Paz-Ares, L. 2009. “Phase II Randomized Study of Plitidepsin (Aplidin), Alone or in Association with L-carnitine, in Patients with Unresectable Advanced Renal Cell Carcinoma”. MARINE DRUGS 7 (1):57-70.
